Navigation Links
Dynatronics Will Request Hearing With Nasdaq Regarding Listing Status
Date:10/15/2009

SALT LAKE CITY, Oct. 15 /PRNewswire-FirstCall/ -- Dynatronics Corporation (Nasdaq: DYNT) today announced that on October 13, 2009, the Company received a letter from Nasdaq stating that the Company has not complied with the $1.00 minimum bid rule and faces delisting from Nasdaq.

Nasdaq provides the Company an opportunity to appeal this determination by requesting a hearing. The hearing panel is authorized to grant up to 180 additional calendar days to regain compliance, if the panel deems it appropriate. The Company's hearing request will permit the Company's securities to remain listed on Nasdaq pending the hearing and a final determination by the Panel.

"We are in the process of preparing our request for a hearing," stated Kelvyn H. Cullimore, Jr., chairman and president of Dynatronics Corp. "With so many positive developments taking place at the Company, including the recently announced return to profitability for the year ended June 30, 2009, we believe we can present a strong plan on appeal and be granted the time necessary to work that plan in order to regain compliance with the rule."

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at http://www.dynatronics.com.

SOURCE Dynatronics Corporation


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
2. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
3. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
4. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
5. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
6. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
7. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
8. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
9. Stemedica Requests Pre-IND Meeting With FDA
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)...  CytRx Corporation (Nasdaq: CYTR ), a ... today announced an interim analysis from its two ... with either gemcitabine or ifosfamide. Both studies combine ... doses of aldoxorubicin. The combinations appear to be ... level of aldoxorubicin (170 mg/m2), impressive tumor responses ...
(Date:5/4/2015)... May 4, 2015  Geneia, a company of ... solutions to improve healthcare efficiencies, today announced a ... Center (BNRC) use Geneia,s advanced analytics solution ... the quality and lower the cost of patient ... outcomes, claims and utilization data from multiple sources ...
(Date:5/4/2015)... INDIANAPOLIS , May 4, 2015 ... released two new reports that provide a comprehensive ... reports highlight how Lilly is evolving its approach ... and capabilities in partnership with others to have ... 2014 Corporate Responsibility Update offers a thorough ...
Breaking Medicine Technology:CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Lilly Releases Corporate Responsibility, Global Health Reports 2Lilly Releases Corporate Responsibility, Global Health Reports 3Lilly Releases Corporate Responsibility, Global Health Reports 4
... , , BERLIN ... NKTR ) presented favorable data today on lead oncology program, ... investigational compound in ovarian cancer. These data were presented at ... Oncology (ESMO) 2009 Joint Multidisciplinary Congress in Berlin, Germany. , ...
... , , , ... a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase ... partial response rate and 50 percent stabilization rate in patients with metastatic ... at the joint 15th Congress of the European CanCer Organisation and 34th ...
Cached Medicine Technology:NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 2NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 3NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 4NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 5Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4
(Date:5/4/2015)... May 04, 2015 San Diego ... ceremony at their brand new, 13,700 square foot facility ... new building will not only provide fertility treatment and ... also offer community and educational events to a number ... is located next door to their current Carmel Valley/Del ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Unlike some camps, the ... imparting knowledge. The goal is to educate first and train ... This ensures that the young runners are building the knowledge ... A few of the topics covered include Effort Based Training, Running ... I used to be? This is not a camp where ...
(Date:5/4/2015)... Pa. (PRWEB) May 04, 2015 Sylvia Hawthorn-Deppen ... the hopes that it would remind others in similar situations ... A Recovery from Chronic Pain and Discovery of New Energy” ... with a new audience via a renewed press campaign. , ... with debilitating pain ,” Hawthorn-Deppen says. “As an adolescent ...
(Date:5/4/2015)... “ Food Cost Calculator ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... manage and efficiently calculate food costs. , The restaurant industry ... the industry has an estimated 1.8 trillion dollar impact on ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 “St. Louis ... the “Gateway to the West,” so it is the ... Veterans Program”, says Dr. Ben Litalien, Chief Development Officer ... Association’s VetFran program and will provide veterans with a ... Zerorez® is proud to have a number of Military ...
Breaking Medicine News(10 mins):Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3
... Fewer Kidneys ,Kidney Donations by the Poor Are on ... with low incomes are more likely to develop kidney failure ... than people of other socioeconomic classes. Because fewer individuals in ... Hospital, University of British Columbia, in Vancouver, Canada) and colleagues ...
... HealthDay Reporter , FRIDAY, Nov. 19 (HealthDay News) -- Computer ... they,ll look after a "nose job," and the majority value ... The "morphing" software, used by plastic surgeons since the 1990s, ... study said. "Having an image of an individual in ...
... (HealthDay News) -- Male teens with disruptive behavior disorders ... in a traffic crash, either as a driver or ... risk is similar to that of epilepsy patients, said ... Canada, and his colleagues. Disruptive behavior disorders include ...
... By Ellin Holohan HealthDay Reporter , ... people ride motorcycles without wearing helmets in the United ... crashes are creating huge medical costs, two new companion ... all traumatic brain injuries sustained in motorcycle crashes involving ...
... 16, 2010) A clinical trial that aims to speed ... of breast cancer now has a designated study site ... University of Colorado Hospital. This study, called I-SPY ... Response with Imaging and Molecular Analysis 2) will evaluate ...
... medicine is a new lead in the search for compounds ... findings, reported by Vanderbilt University Medical Center researchers in the ... fresh approach for developing therapeutics that target the pathway. More ... second deadliest type of cancer in the developed world ...
Cached Medicine News:Health News:Efforts needed to address disparities in kidney transplantation 2Health News:Efforts needed to address disparities in kidney transplantation 3Health News:Efforts needed to address disparities in kidney transplantation 4Health News:Computer Imaging Adds to 'Nose Job' Satisfaction: Study 2Health News:Computer Imaging Adds to 'Nose Job' Satisfaction: Study 3Health News:Behavior Disorders Boost Crash Risk for Teen Boys: Study 2Health News:Young Motorcycle Riders Suffering More Brain Injuries 2Health News:Young Motorcycle Riders Suffering More Brain Injuries 3Health News:I-SPY 2 study speeds up treatment for breast cancer 2Health News:I-SPY 2 study speeds up treatment for breast cancer 3Health News:New path for colon cancer drug discovery 2
Rounded tip spatula with 20 gauge shaft. Black finish for reduced glare....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 110o. Most popular size or model....
10 mm angled tip with indentation on side and gently curved blade. Round knurled handle with polished finish. Indentation: left side....
0.5 mm x 15 mm angled round blade with smoothly pointed tip and gently curved blade. Round knurled handle with polished finish....
Medicine Products: